US 11,661,402 C1 (12,559th)
PSMA-targeting compounds and uses thereof
Martin G. Pomper, Baltimore, MD (US); Ronnie C. Mease, Fairfax, VA (US); Ying Chen, Timonium, MD (US); and Sangeeta Ray, Ellicott City, MD (US)
Filed by The Johns Hopkins University, Baltimore, MD (US)
Assigned to THE JOHNS HOPKINS UNIVERSTY, Baltimore, MD (US)
Reexamination Request No. 90/015,307, Oct. 2, 2023.
Reexamination Certificate for Patent 11,661,402, issued May 30, 2023, Appl. No. 17/718,812, Apr. 12, 2022.
Application 14/243,535 is a division of application No. 13/257,499, granted, now 9,056,841, previously published as PCT/US2010/028020, filed on Mar. 19, 2010.
Application 90/015,307 is a continuation of application No. 17/474,497, filed on Sep. 14, 2021, abandoned.
Application 17/474,497 is a continuation of application No. 17/331,113, filed on May 26, 2021.
Application 17/331,113 is a continuation of application No. 16/820,052, filed on Mar. 16, 2020, granted, now 11,021,450.
Application 16/820,052 is a continuation of application No. 16/704,137, filed on Dec. 5, 2019, abandoned.
Application 16/704,137 is a continuation of application No. 15/618,788, filed on Jun. 9, 2017, abandoned.
Application 15/618,788 is a continuation in part of application No. 14/243,535, filed on Apr. 2, 2014, granted, now 9,776,977.
Claims priority of provisional application 61/248,934, filed on Oct. 6, 2009.
Claims priority of provisional application 61/248,067, filed on Oct. 2, 2009.
Claims priority of provisional application 61/161,485, filed on Mar. 19, 2009.
Claims priority of provisional application 61/161,484, filed on Mar. 19, 2009.
Ex Parte Reexamination Certificate issued on Mar. 27, 2024.
Int. Cl. C07D 257/02 (2006.01); A61K 49/00 (2006.01); A61K 51/04 (2006.01); A61P 35/00 (2006.01); C07D 209/12 (2006.01); C07D 209/14 (2006.01); C07D 209/24 (2006.01); C07D 213/04 (2006.01); C07D 249/04 (2006.01); C07D 255/02 (2006.01); C07D 311/14 (2006.01); C07D 311/20 (2006.01); C07D 311/82 (2006.01); C07F 5/02 (2006.01); C07F 13/00 (2006.01); G01N 33/50 (2006.01)
CPC C07D 257/02 (2013.01) [A61K 49/0032 (2013.01); A61K 49/0052 (2013.01); A61K 51/0421 (2013.01); A61K 51/044 (2013.01); A61K 51/0446 (2013.01); A61K 51/0453 (2013.01); A61K 51/0472 (2013.01); C07D 209/12 (2013.01); C07D 209/14 (2013.01); C07D 209/24 (2013.01); C07D 213/04 (2013.01); C07D 249/04 (2013.01); C07D 255/02 (2013.01); C07D 311/14 (2013.01); C07D 311/20 (2013.01); C07D 311/82 (2013.01); C07F 5/027 (2013.01); C07F 13/005 (2013.01); G01N 33/5091 (2013.01); A61P 35/00 (2018.01); G01N 2800/342 (2013.01)]
AS A RESULT OF REEXAMINATION, IT HAS BEEN DETERMINED THAT:
The patentability of claims 1-19 is confirmed.
1. A compound having the structure:

OG Complex Work Unit Chemistry
wherein:
Z is tetrazole or CO2Q;
each Q is independently selected from hydrogen or a protecting group;
a is 1, 2, 3, or 4;
R is each independently II or C1-C4 alkyl;
Ch is a metal chelating moiety optionally including a chelated metal, wherein Ch optionally includes any additional atoms or linkers necessary to attach the metal chelating moiety to the rest of the compound;
W is —NRC(O)—, —NRC(O)NR—, NRC(S)NR—, —NRC(O)O—, —OC(O)NR—, —OC(O)—, —C(O) NR—, or —C(O)O—;
Y is —C(O)—, —NRC(O)—, —NRC(S)—, —OC(O);
V is —C(O)', —NRC(O)—, —NRC(S)—, or —OC (O)—;
m is 1, 2, 3, 4, 5, or 6;
n is 1, 2, 3, 4, 5 or 6;
p is 1, 2, or 3, and when p is 2 or 3,each R1 may be the same or different;
is II, C1-C6 alkyl, C2-C12 aryl, or C4-C16 alkylaryl;
R2 and R3 are independently H, CO2H, or CO2R4, wherein R4 is a C1-C6 alkyl, C2-C12 aryl, or C4-C16 alkylaryl, wherein when one of R2 R3 is CO2H or CO2R4, the other is H, and when p is 0, one of R2 and R3 is CO2R4, and the other is H.